Clinical trial
Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT…
NCT00430469 · AM-Pharma, Industry · Withdrawn
Key facts
| NCT number | NCT00430469 |
|---|---|
| Title | Safety of hLF1-11 for the Treatment of Infectious Complications Among HSCT Recipients |
| Official title | Safety of a 0.5mg Dose of hLF1-11 Given for 10 Consecutive Days to Autologous Haematopoietic Stem Cell Transplant Recipients |
| Lead sponsor | AM-Pharma, Industry |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Fungal Infection, Bacterial Infection |
| Intervention type | Drug |
| Interventions | human lactoferrin (hLF1-11) |
| Enrollment | 0 |
| Start date | Nov 1, 2008 |
| Primary completion | Mar 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Feb 2, 2007 |
| Last update posted | Jun 30, 2015 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: